Breaking

Two cannabinoids have opposing effects on SARS-CoV-2 in culture - Ars Technica
Jan 21, 2022 1 min, 1 sec

Over the course of the COVID-19 pandemic, researchers have tested a wide range of drugs to see if they inhibit the virus.

Most of these tests didn't end up going anywhere; even the few drugs that did work typically required concentrations that would be impossible to achieve inside human cells.

In any case, the researchers behind the new work (primarily at the University of Chicago) started with lung cancer cells that produce the protein that SARS-CoV-2 uses to infect cells and dumped both the virus and CBD on the cells.

In any case, this is where the work starts to move beyond the hundreds of similar "let's throw drugs on some cells" studies that have been done: the researchers do their best to figure out how CBD works.

They checked whether it stopped human cells from producing the protein that the virus latches onto when infecting them, but that wasn't the cause.

And they confirmed that viruses could still get inside cells by using the SARS-CoV-2 spike protein.

But once the virus gets inside, not a lot seems to happen.

Very little of the spike protein gets made in infected cells treated with CBD, and levels stay low for up to 15 hours after infection.

RECENT NEWS

SUBSCRIBE

Get monthly updates and free resources.

CONNECT WITH US

© Copyright 2024 365NEWSX - All RIGHTS RESERVED